Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853113 | 1.00 | TSHR (0.46) | TSHRALDH1A1EP300SMN1; SMN2GRIK1 | |
| SCHEMBL1206975 | 0.84 | TSHR (0.46) | TSHRALDH1A1EP300LMNAMEN1 | |
| SCHEMBL1206974 | 0.84 | TSHR (0.46) | TSHRALDH1A1EP300LMNAMEN1 | |
| SCHEMBL14481044 | 0.84 | TSHR (0.46) | TSHRALDH1A1EP300LMNAMEN1 | |
| SCHEMBL14481045 | 0.84 | TSHR (0.46) | TSHRALDH1A1EP300LMNAMEN1 | |
| SCHEMBL29284363 | 0.82 | TSHR (0.50) | TSHRALDH1A1EP300LMNAMEN1 | |
| SCHEMBL29284543 | 0.82 | TSHR (0.50) | TSHREP300LMNAMEN1KMT2A | |
| SCHEMBL31317388 | 0.81 | EP300 (0.50) | TSHRALDH1A1EP300SMN1; SMN2LMNA | |
| SCHEMBL29284318 | 0.80 | TSHR (0.44) | TSHRALDH1A1EP300LMNAMEN1 | |
| SCHEMBL846672 | 0.79 | TSHR (0.48) | TSHRALDH1A1EP300GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723550-B2 | Process for preparing organic compounds | NOVARTIS AG (CH) | 2010-05-25 | — | — | US | disclosed |
| EP-1943205-B1 | PROCESS FOR PREPARING OF 2-ALKYL-3-ARYL-PROP-2 ENE-1-OLS | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-20090105503-A1 | Process for Preparing organic compounds | NOVARTIS PHARMA AG (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-1943205-A1 | PROCESS FOR PREPARING OF 2-ALKYL 3-ARYL PROP-2-2ENE-1-OLS | Speedel Experimenta AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008055941-A1 | PROCESS FOR PREPARING OF 2-ALKYL-3-ARYL-PROP-2 ENE-1-OLS | SPEEDEL EXPERIMENTA AG (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105503-A1 | Process for Preparing organic compounds | C1S, C9, C5 | TSHR 324/4885ALDH1A1 1478/4885EP300 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.